Stock markets find a floor as Chinese data soothe nerves
August 8, 2019
Viacom beats quarterly revenue, profit estimates as ad revenue rebounds
August 8, 2019

Bayer buys BlueRock in $600 million bet on stem cell therapies

German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline.

Powered by WPeMatico